Literature DB >> 24561457

The curative effect of fucoidan on visceral leishmaniasis is mediated by activation of MAP kinases through specific protein kinase C isoforms.

Gunjan Sharma1, Susanta Kar1, Writoban Basu Ball1, Kuntal Ghosh2, Pijush K Das1.   

Abstract

Fucoidan can cure both antimony-sensitive and antimony-resistant visceral leishmaniasis through immune activation. However, the signaling events underlying this cellular response remain uncharacterized. The present study reveals that fucoidan induces activation of p38 and ERK1/2 and NF-κB DNA binding in both normal and Leishmania donovani-infected macrophages, as revealed by western blotting and electrophoretic mobility shift assay (EMSA), respectively. Pharmacological inhibition of p38, ERK1/2 or the NF-κB pathway markedly attenuated fucoidan-induced pro-inflammatory cytokine synthesis and inducible nitric oxide synthase (iNOS) gene transcription, resulting in a reduction of parasite clearance. To decipher the underlying mechanism of fucoidan-mediated parasite suppression, the expression and functionality of various protein kinase C (PKC) isoforms were evaluated by immunoblotting and enzyme activity assay. Fucoidan elicited an increase in expression and activity of PKC-α, -βI and -βII isoforms in infected macrophages. Functional knockdown of PKC-α and -β resulted in downregulation of p38 and ERK1/2, along with a marked reduction of IL-12 and TNF-α production in fucoidan-treated infected macrophages. Collectively, these results suggest that the curative effect of fucoidan is mediated by PKC-dependent activation of the mitogen-activated protein kinase (MAPK)/NF-κB pathway, which ultimately results in the production of nitric oxide (NO) and disease-resolving pro-inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24561457      PMCID: PMC4085487          DOI: 10.1038/cmi.2013.68

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  36 in total

1.  Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi.

Authors:  K R Gantt; T L Goldman; M L McCormick; M A Miller; S M Jeronimo; E T Nascimento; B E Britigan; M E Wilson
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

2.  Reciprocal regulation of protein kinase C isoforms results in differential cellular responsiveness.

Authors:  Raki Sudan; Neetu Srivastava; Surya Prakash Pandey; Subrata Majumdar; Bhaskar Saha
Journal:  J Immunol       Date:  2012-01-23       Impact factor: 5.422

3.  Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favorable T cell response.

Authors:  L Das; N Datta; S Bandyopadhyay; P K Das
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

4.  PKC- and ERK-dependent activation of I kappa B kinase by lipopolysaccharide in macrophages: enhancement by P2Y receptor-mediated CaMK activation.

Authors:  B C Chen; W W Lin
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

5.  Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells.

Authors:  M Goebeler; R Gillitzer; K Kilian; K Utzel; E B Bröcker; U R Rapp; S Ludwig
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

6.  Ligands of macrophage scavenger receptor induce cytokine expression via differential modulation of protein kinase signaling pathways.

Authors:  H Y Hsu; S L Chiu; M H Wen; K Y Chen; K F Hua
Journal:  J Biol Chem       Date:  2001-06-04       Impact factor: 5.157

7.  Selective impairment of protein kinase C isotypes in murine macrophage by Leishmania donovani.

Authors:  S Bhattacharyya; S Ghosh; P Sen; S Roy; S Majumdar
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

8.  NF-kappa B2 is required for optimal CD40-induced IL-12 production but dispensable for Th1 cell Differentiation.

Authors:  Kendra Speirs; Jorge Caamano; Michael H Goldschmidt; Christopher A Hunter; Phillip Scott
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

9.  Fucoidan cures infection with both antimony-susceptible and -resistant strains of Leishmania donovani through Th1 response and macrophage-derived oxidants.

Authors:  Susanta Kar; Gunjan Sharma; Pijush K Das
Journal:  J Antimicrob Chemother       Date:  2011-01-14       Impact factor: 5.790

10.  Fucoidan extract induces apoptosis in MCF-7 cells via a mechanism involving the ROS-dependent JNK activation and mitochondria-mediated pathways.

Authors:  Zhongyuan Zhang; Kiichiro Teruya; Hiroshi Eto; Sanetaka Shirahata
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

View more
  8 in total

1.  Highly scalable, closed-loop synthesis of drug-loaded, layer-by-layer nanoparticles.

Authors:  Santiago Correa; Ki Young Choi; Erik C Dreaden; Kasper Renggli; Aria Shi; Li Gu; Kevin E Shopsowitz; Mohiuddin A Quadir; Elana Ben-Akiva; Paula T Hammond
Journal:  Adv Funct Mater       Date:  2016-01-03       Impact factor: 18.808

2.  TLR2 dimer-specific ligands selectively activate protein kinase C isoforms in Leishmania infection.

Authors:  Arkajyoti Mukherjee; Sayoni Roy; Ashok Patidar; Neelam Bodhale; Jagneswar Dandapat; Bhaskar Saha; Arup Sarkar
Journal:  Immunology       Date:  2021-06-07       Impact factor: 7.215

Review 3.  The pathogenicity and virulence of Leishmania - interplay of virulence factors with host defenses.

Authors:  Anand Kumar Gupta; Sonali Das; Mohd Kamran; Sarfaraz Ahmad Ejazi; Nahid Ali
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

Review 4.  Nanostructured delivery systems with improved leishmanicidal activity: a critical review.

Authors:  Natascia Bruni; Barbara Stella; Leonardo Giraudo; Carlo Della Pepa; Daniela Gastaldi; Franco Dosio
Journal:  Int J Nanomedicine       Date:  2017-07-26

Review 5.  Antiparasitic Effects of Sulfated Polysaccharides from Marine Hydrobionts.

Authors:  Natalya N Besednova; Tatyana S Zaporozhets; Boris G Andryukov; Sergey P Kryzhanovsky; Svetlana P Ermakova; Tatyana A Kuznetsova; Anastasia N Voronova; Mikhail Y Shchelkanov
Journal:  Mar Drugs       Date:  2021-11-12       Impact factor: 5.118

Review 6.  Therapies from Fucoidan: An Update.

Authors:  Janet Helen Fitton; Damien N Stringer; Samuel S Karpiniec
Journal:  Mar Drugs       Date:  2015-09-16       Impact factor: 5.118

Review 7.  Fucoidans: Downstream Processes and Recent Applications.

Authors:  Ahmed Zayed; Roland Ulber
Journal:  Mar Drugs       Date:  2020-03-18       Impact factor: 5.118

8.  Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans.

Authors:  Margherita Ortalli; Stefania Varani; Giorgia Cimato; Ruben Veronesi; Arianna Quintavalla; Marco Lombardo; Magda Monari; Claudio Trombini
Journal:  J Med Chem       Date:  2020-10-22       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.